comparemela.com

Latest Breaking News On - Novarti lucentis - Page 1 : comparemela.com

Regeneron hit with DOJ complaint that it hid 'hundreds of millions' in Eylea credit card processing fees from Medicare

Regeneron hit with DOJ complaint that it hid 'hundreds of millions' in Eylea credit card processing fees from Medicare
fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.

Massachusetts
United-states
Novarti-lucentis
Deloitte
Novartis
Us-district-court
Department-of-justice
Besse-medical
Fierce-pharma
False-claims
False-claims-act
Inflation-reduction

PulseSight Therapeutics Launches to Advance Non-viral Gene Therapies with Disruptive Minimally-Invasive Delivery Technology for Severe Retinal Diseases

PulseSight Therapeutics Launches to Advance Non-viral Gene Therapies with Disruptive Minimally-Invasive Delivery Technology for Severe Retinal Diseases
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

South-korea
France
Paris
France-general
Korea
Pureos-bioventures
Novarti-lucentis
Joon-hyun
Novarti-beovu
Kostas-kaloulis
Francine-behar-cohen
Regeneron-eylea

NHS wins legal fight with pharma over off-label Avastin

NHS wins legal fight with pharma over off-label Avastin
pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.

United-kingdom
Sheuli-porkess
Novarti-lucentis
Julie-wood
Bayer-eylea
Department-of-health
Novartis
Commissioning-groups
Mrs-justice-whipple
Deputy-chief-scientific-officer
United-kingdom-government
Social-care

Fierce Pharma Asia—Enhertu's big win; Biogen-Samsung's Lucentis biosimilar; Clover's COVID vaccine data

Fierce Pharma Asia—Enhertu's big win; Biogen-Samsung's Lucentis biosimilar; Clover's COVID vaccine data
fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.

China
Delaware
United-states
Japan
India
Hong-kong
Japanese
Chinese
Johnson-erleada
Samsung-biologics
Daiichi-sankyo
Samsung-bioepis

Thanks to Coherus, another China-made PD-1 is making its way to the U.S. Can it find room in a crowded market?

Feb 2, 2021 10:50am Coherus BioSciences is shelling out $150 million upfront for U.S. and Canadian rights to Junshi Biosciences’ PD-1 inhibitor toripalimab. (Kritchanut/iStock/Getty Images Plus/Getty Images) On the heels of Novartis licensing BeiGene’s tislelizumab, another China-made PD-1 inhibitor has found itself a new U.S. collaborator in a company that’s just pivoting to immuno-oncology. Coherus BioSciences is shelling out $150 million upfront for U.S. and Canadian rights to Junshi Biosciences’ anti-PD-1 antibody toripalimab, which was first approved in China for previously treated melanoma in late 2018. Up to $380 million in milestone payments and a 20% royalty on net sales are also up for grabs.

China
California
United-states
Canada
Chinese
Canadian
Abbvie-humira
Denny-lanfear
Junshi-bioscience
Roche-avastin
Novarti-lucentis
Coherus-biosciences

vimarsana © 2020. All Rights Reserved.